Jasper Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JSPR research report →
Range $2 – $3
Price Chart
About the company
Jasper Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
- CEO
- Jeetinder Singh Mahal
- IPO
- 2020
- Employees
- 22
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on JSPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.10M
- P/E
- -0.35
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 11.38
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -618.87%
- ROIC
- -1305.04%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,056,000+0.0%
- Op Income
- $-80,518,000
- Net Income
- $-75,801,000-6.4%
- EPS
- $-3.95+19.2%
- OCF Growth
- -23.3%
- FCF Growth
- -22.2%
- 52W High
- $2.69
- 52W Low
- $0.32
- 50D MA
- $0.68
- 200D MA
- $0.97
- Beta
- 3.04
- RSI (14)
- 40
- Avg Volume
- 1.39M
No earnings-call transcripts are available for JSPR yet.
- Free Float
- 84.8%
- Shares Outstanding
- 33.27M
- Float Shares
- 13.78M
of shares held by institutions
60 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Velan Capital Investment Management LP | 2.67M | 0 |
| Acorn Capital Advisors, LLC | 1.44M | ▲ 26.67K |
| Kingdon Capital Management, L.L.C. | 1.35M | 0 |
| Vanguard Group Inc | 1.33M | ▲ 293.67K |
| Vanguard Capital Management LLC | 1.17M | ▼ 576 |
| Rock Springs Capital Management LP | 1.10M | 0 |
| Carlyle Group Inc. | 1.07M | 0 |
| Qiming U.S. Ventures Management, LLC | 928.96K | 0 |
| Gsa Capital Partners Llp | 534.70K | ▲ 515.61K |
| Millennium Management LLC | 486.93K | ▼ 1.13M |
| Lion Point Capital, LP | 465.00K | 0 |
| Geode Capital Management, LLC | 263.81K | ▼ 53.87K |
Held by 23 ETFs
Biggest fund positions in JSPR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | WIGGANS THOMAS G | other | 7,500 |
| Jul 31, 26 | Lucas Svetlana | other | 7,500 |
| Jul 31, 26 | Crutcher Patrick J | other | 7,500 |
| Jul 31, 26 | EMSTER KURT VON | other | 7,500 |
| Jul 31, 26 | Shizuru Judith Anne | other | 7,500 |
| Jul 16, 26 | Keenan Greg | other | 103,204 |
| Jul 16, 26 | Keenan Greg | other | 92,278 |
| Jul 20, 26 | Ros Matthew E | buy | 881 |
| Jul 16, 26 | Song Wenru | other | 0 |
| Jul 16, 26 | Song Wenru | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JSPR coverage
Recent articles, reports, and earnings notes.
No research on JSPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JSPR report →Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
globenewswire.com · Sep 15
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 9
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 14
Jasper Closes Kira Deal, Extends Cash Runway
benzinga.com · Jul 17
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
globenewswire.com · Jul 16
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
zacks.com · Jun 3
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
globenewswire.com · Jun 1
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.